ID: MRFR/HC/5746-CR | January 2019 | Region: Global | 156 pages
MRFR’s study projects a strong growth for the pericarditis market during the forecast period (2018-2023). Growing prevalence of cardiac disorders worldwide and improving healthcare infrastructure in emerging economies creating opportunities for market players. Americas continues to be the key investment destination for drug companies, with countries such as the U.S., Canada, Mexico and Brazil occupying the leading spots. On a global level, the pericarditis market stood at a valuation of USD 1,750.38 Mn in 2017. Opportunities are likely to get better in emerging markets such as China and India in the forthcoming years. Rising healthcare spending and increased healthcare penetration is providing an impetus to the market in these countries.
This MRFR study presents a holistic viewpoint of the pericarditis market. A revenue forecast for five-years (2018-2023) is also included in the study. It thoroughly discusses all the elements that may have some sort of impact on the pericarditis market during the assessment period. The scope of the discussion also covers different types of pericarditis such as acute pericarditis, chronic pericarditis and recurrent pericarditis. In addition, study shed a light on diagnosis and treatment options available.
Novartis International AG, Pfizer Inc., AstraZeneca Plc., PerkinElmer, Inc., Sanofi, Johnson & Johnson Services, Inc., Reckitt Benckiser Group Plc, FUJIFILM Holdings Corporation, Bayer AG, Merck & Co., Inc. and Allergan plc.
The pericarditis market report offers insights into the leading market players and presents an assessment of their current market position. Company information with regards to revenue, segmental share, geographical income, SWOT, growth strategies, new product launch, M&A activities, and the latest R&D initiatives is also available in the report.
MRFR relies on a robust research model for conducting industry analysis. The analysis pattern may differ from sector to sector, but the fundamental structure remains unshaken. Emphasis is placed on maintaining a deep-diving research dogma. For this, interviews and meetings are conducted with opinion holders, thought leaders, and key executives. Also, data is collected from secondary research materials such as SEC filings, dossiers, paid database services, annual report published by industry leaders, etc. The gathered data undergoes a multi-level evaluation process making it error-free. In addition, both top-down and bottom-up approaches are applied to add value to research findings.
For the scope of the research, MRFR’s report offers a comprehensive segmental analysis of the pericarditis market
Pericarditis Market, By Type
Pericarditis Market, By Diagnosis and Treatment
Pericarditis Market, By End User
Pericarditis Market, By Region
Frequently Asked Questions (FAQ) :
Pericaditis market is projected to grow at a 7.96% CAGR between 2020-2027.
Pericaditis market is predicted to touch USD 2,741.39 million by 2023.
The Americas is expected to lead the pericaditis market.
Favorable reimbursement and the advent of robot-assisted cardiac surgeries are the key factors driving the pericaditis market.
Certain side effects may limit the pericaditis market.
Global Pericarditis Market: Company Landscape
The global pericarditis market is characterized by the presence of many global, regional, and local vendors. The market is highly competitive with all the players competing to gain the market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, quality, and reliability. It is decisive for vendors to provide cost-efficient and high-quality products, to survive and succeed in an intensely competitive and growing market environment.
The growth of market vendors is dependent on market conditions, government support, and industry development. Thus, vendors should focus on expanding geographically and improving their products. They primarily focus on the development of novel products. Although international players are dominating the market, regional and foreign players with small market shares also have a presence. The international players are likely to strengthen their presence worldwide through acquisitions during the forecast period. It has also been forecast that improvement of the global economic scenario combined with efforts to enhance infrastructure in emerging nations, is fueling the market growth, thereby making it an ideal time for new products and to increase the global market share.
Many leading players are concentrated in the Americas owing to the strengthening healthcare system, well-established market, high healthcare expenditures, and numerous opportunities for growth. These players have expanded their market in other regions as well. Furthermore, companies such as Pfizer Inc., AstraZeneca Plc, Novartis International AG, Allergan plc., and Merck & Co., Inc. are top five market players in this market. Apart from this, Bayer AG, Reckitt Benckiser Group Plc., PerkinElmer, Inc., FUJIFILM Holdings Corporation, Sanofi, and Johnson & Johnson Services, Inc. are some of the well-established players in the global pericarditis market.
Pfizer Inc. (Pfizer) is a leading research-based biopharmaceutical company that develops medicines and vaccines for a wide range of medical disciplines including cardiology, immunology, oncology, diabetology/endocrinology, and neurology. Pfizer additionally teams up with healthcare providers, governments, and local communities to support and expand access to reliable and affordable healthcare around the world. The company operates worldwide in the Americas, Europe, Asia-Pacific, and the Middle East and Africa. In July 2017 Pfizer Inc. extended the collaboration with Catalent, Inc, a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products for the development and manufacture of Advil Liqui-Gels.
Novartis International AG (Novartis) is a Swiss multinational pharmaceutical company that researches, develops, manufactures, and distributes a wide range of healthcare products globally. The company operates through three segments, namely, innovative medicines, Sandoz, and Alcon. The company provides products that find applications in cancer, cardio-metabolic, immunology and dermatology, ophthalmology, neuroscience, and respiratory diseases.
Allergan plc. (Allergan) is a pharmaceutical company with a motive of manufacturing, developing, and commercializing pharmaceutical products, biological products, and devices for patients worldwide. The company has a wide range of products which provide effective treatments for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories. The company has operations across the globe in regions such as Europe, Africa, Americas, and Asia-Pacific.
Merck & Co., Inc. (Merck) is also known as MSD outside the US and Canada. The company operates through its four segments, namely, pharmaceutical, animal health, healthcare services, and alliances. The company offers therapeutic and preventive agents to treat arthritis and pain, cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, and other diseases. Merck works with clients and works in more than 140 countries to provide inventive healthcare products.